Eli Lilly and Company, Moderna, and Johnson & Johnson are the three Healthcare stocks to watch today, according to MarketBeat's stock screener tool. Healthcare stocks are shares of publicly traded companies that provide healthcare-related products or services, such as pharmaceuticals, medical devices, biotechnology, hospitals, and health insurance. Investors may buy them to gain exposure to the healthcare sector, whose performance can be influenced by factors such as medical innovation, regulation, and demand for care. These companies had the highest dollar trading volume of any Healthcare stocks within the last several days.
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Shares of NYSE:LLY traded up $7.42 during midday trading on Friday, reaching $1,372.15. 3,802,992 shares of the company were exchanged, compared to its average volume of 2,624,130. The firm has a market cap of $1.29 trillion, a PE ratio of 44.54, a P/E/G ratio of 1.77 and a beta of 0.40. Eli Lilly and Company has a fifty-two week low of $850.51 and a fifty-two week high of $1,453.00. The stock has a fifty day simple moving average of $1,215.24 and a two-hundred day simple moving average of $1,101.16. The company has a quick ratio of 1.00, a current ratio of 1.39 and a debt-to-equity ratio of 1.17.
Read Our Latest Research Report on LLY
Moderna (MRNA)
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Shares of MRNA traded up $12.73 during midday trading on Friday, hitting $254.19. The stock had a trading volume of 16,295,043 shares, compared to its average volume of 18,981,452. The company has a 50 day simple moving average of $191.85 and a two-hundred day simple moving average of $91.51. Moderna has a twelve month low of $22.28 and a twelve month high of $267.50. The firm has a market cap of $101.48 billion, a price-to-earnings ratio of -31.81 and a beta of 1.16. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.18.
Read Our Latest Research Report on MRNA
Johnson & Johnson (JNJ)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Shares of NYSE:JNJ traded up $3.82 during mid-day trading on Friday, reaching $276.14. 8,859,790 shares of the stock were exchanged, compared to its average volume of 7,536,766. The stock's 50 day simple moving average is $265.91 and its 200-day simple moving average is $248.30. Johnson & Johnson has a one year low of $185.12 and a one year high of $282.02. The company has a market cap of $664.76 billion, a P/E ratio of 41.84, a P/E/G ratio of 2.67 and a beta of 0.22. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44.
Read Our Latest Research Report on JNJ
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
